Clinical Trial Update: Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating APX-115 for preventing Contrast-Induced Acute Kidney Injury in patients undergoing percutaneous coronary intervention is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Acute Kidney Injury

Drugs mentioned

• APX-115

Snippet

Sponsor: Aptabio Therapeutics, Inc. | Conditions: Contrast Induced Acute Kidney Injury | Phase 2 | Status: RECRUITING